United States Patent and Trademark Office

1

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/724,179 12/01/2003		12/01/2003	Katsutoshi Sakata	246080US0CONT	1342	
22850	7590 11/24/2006			EXAMINER		
C. IRVIN N		LAND CCLELLAND, MAI	COLEMAN, BRENDA LIBBY			
1940 DUKE	-	•	ART UNIT	PAPER NUMBER		
ALEXAND:	RIA, VA	22314		1624		

DATE MAILED: 11/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applic	ation No.	Applicant(s)	
	10/724	10/724,179 SAKATA ET		AL.	
Office :	Exami	ner	Art Unit		
		Brenda	L. Coleman	1624	
The MAILI Period for Reply	NG DATE of this commun	nication appears on	the cover sheet	with the correspondence a	ddress
WHICHEVER IS I - Extensions of time ma after SIX (6) MONTHS - If NO period for reply i - Failure to reply within Any reply received by	ONGER, FROM THE N y be available under the provisions from the mailing date of this comi s specified above, the maximum s	MAILING DATE OF s of 37 CFR 1.136(a). In no munication. tatutory period will apply an y will, by statute, cause the	THIS COMMUN be event, however, may ad will expire SIX (6) Mo application to become	a reply be timely filed ONTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).	:
Status	•				
1)⊠ Responsive	to communication(s) file	ed on 15 Sentembe	or 2006		
2a) This action		2b)⊠ This action i			
<u>'</u>		•	•	atters, prosecution as to th	e merite is
	cordance with the pract		-	•	o monto lo
Disposition of Claim		and an parto			
<u> </u>		!:!:			
	37 is/are pending in the a	• •	nanaida-ati		
	bove claim(s) <u>26-37</u> is/a	re withdrawn from t	consideration.		
· · · · · · · · · · · · · · · · · · ·	is/are allowed.				
6)⊠ Claim(s) <u>1-2</u>					
	is/are objected to.	ation and/or alastic	n roquiroment		
, ,,	are subject to restri	Ction and/or election	n requirement.		
Application Papers					
9) The specific	ation is objected to by th	e Examiner.			
10)☐ The drawing	(s) filed on is/are	: a)□ accepted or	b) ☐ objected to	b by the Examiner.	
Applicant ma	y not request that any obje	ction to the drawing(s	s) be held in abey	ance. See 37 CFR 1.85(a).	
Replacement	t drawing sheet(s) including	g the correction is req	uired if the drawin	g(s) is objected to. See 37 C	FR 1.121(d).
11)☐ The oath or	declaration is objected to	o by the Examiner.	Note the attache	ed Office Action or form P	TO-152.
Priority under 35 U.S	S.C. § 119				
	ment is made of a claim Some * c)⊡ None of:	for foreign priority	under 35 U.S.C.	§ 119(a)-(d) or (f).	
1.⊠ Certif	ied copies of the priority	documents have b	een received.		
2. Certif	ied copies of the priority	documents have b	een received in	Application No	
				n received in this National	Stage
applic	ation from the Internation	onal Bureau (PCT F	Rule 17.2(a)).		
* See the attac	hed detailed Office action	on for a list of the ce	ertified copies no	ot received.	
	•				<i>)</i>
Attachment(s)	. O''1 (DTO 200)				
Notice of References Notice of Draftsperso	s Cited (PTO-892) on's Patent Drawing Review (F	PTO-948)		y Summary (PTO-413) o(s)/Mail Date	
_	re Statement(s) (PTO/SB/08)	. 5 0 . 0,		Informal Patent Application	
Paper No(s)/Mail Date			6) Other: _	·	

DETAILED ACTION

Claims 1-37 are pending in the application.

This action is in response to applicants' amendment filed September 15, 2006.

Claims 1-37 have been amended.

Response to Amendment

Applicant's amendments filed September 15, 2006 have been fully considered with the following effect:

1. With regards to the 35 U.S.C. § 112, first paragraph rejection of claims 22-25 labeled paragraph 4 of the last office action, the applicants' arguments have been fully considered, however they were not found persuasive. Applicants' state that the specification discloses that antagonists to calcium channels are considered to be effective against diseases of the digestive tract. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims where the disorder is any functional disease of the digestive tract. As stated in the last office action it is difficult to treat many of the disorders claimed herein. The method of use of the compounds of claim 1 in the treatment of a functional disease of the digestive tract includes diseases such as stomach cancer, Chron's disease, ulcers which are caused by bacteria, etc. which are not associated with calcium channel blockers.

Where the utility is unusual or difficult to treat or speculative, the examiner has authority to require evidence that tests relied upon are reasonably predictive of in vivo

Art Unit: 1624

efficacy by those skilled in the art. See In re Ruskin, 148 USPQ 221; Ex parte Jovanovics, 211 USPQ 907; MPEP 2164.05(a).

Patent Protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. Tossing out the mere germ of an idea does not constitute enabling disclosure. Genentech Inc. v. Novo Nordisk 42 USPQ2d 1001.

As stated in the MPEP, 2164.08 "[t]he Federal Circuit has repeatedly held that the specification must teach those skilled in the art how to make and use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557. 1561 27 USPQZd 1510, 1513 (Fed. Cir. 1993). Nevertheless, not everything necessary to practice the invention need be disclosed. In fact, what is well known is best omitted. In re Buchner, 929 F.2d 660, 661, 18 USPQZd 1331, 1332 (Fed. Cir. 1991). All that is necessary is that one skilled in the art be able to practice the claimed invention, given the level of knowledge and skill in the art. Further the scope of enablement must only bear a reasonable correlation to the scope of the claims. See, e.g., In re Fisher, 427 F.2d 833, 839,166 USPQ 18, 24 (CCPA 1970). As concerns the breadth of a claim relevant to enablement, the only relevant concern should be whether the scope of enablement provided to one skilled in the art by the disclosure is commensurate with the scope of protection sought by the claims. In re Moore, 439 F.2d 1232, 1236, 169 USPQ 236, 239 (CCPA 1971). See also Plant Genetic Sys., N.V. v. DeKalb Genetics Corp., 315 F.3d 1335, 1339, 65 USPQZd 1452, 1455 (Fed. Cir. 2003) (alleged pioneer status of invention irrelevant to enablement determination."

Application/Control Number: 10/724,179

Art Unit: 1624

Claims 22-25 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention, for reasons of record and stated above.

Page 4

- 2. The applicants' amendments and arguments are sufficient to overcome the 35 USC § 112, second paragraph rejections labeled paragraph 5b), e), f) and g) of the last office action, which are hereby **withdrawn**. However, with regards to the 35 U.S.C. § 112, second paragraph rejection labeled 5a), c) and d) of the last office action, the applicant's amendments and remarks have been fully considered but they are not persuasive.
 - a) The applicant's stated that they have been obviated by appropriate amendment. However, claims 1 and 12 have not been amended with respect to the definition of R⁹, R¹⁰, R¹¹, R¹² and R¹³.

Claims 1-9 and 12-25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above.

c) The applicant's stated that they have been obviated by appropriate amendment. However, claim 1 and claims dependent thereon have not been

Application/Control Number: 10/724,179

Art Unit: 1624

amended with respect to the variables R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13. It is not known if the applicants intended superscripts.

Page 5

Claims 1-25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above.

d) The applicant's stated that they have been obviated by appropriate amendment. However, claim 1 claims dependent thereon have not been amended with respect to the definitions of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹³.

Claims 1-9 and 12-25 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, for reasons of record and stated above.

In view of the amendment dated September 15, 2006, the following new grounds of rejection apply:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claim 1 is rejected under 35 U.S.C. 112, first paragraph, because the

specification, while being enabling for other forms, does not reasonably provide enablement for solvates. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. The claim is drawn to solvates. But the numerous examples presented all failed to produce a solvate. These cannot be simply willed into existence. As was stated in *Morton International Inc. v. Cardinal Chemical Co.*, 28 USPQ2d 1190 "The specification purports to teach, with over fifty examples, the preparation of the claimed compounds with the required connectivity. However ... there is no evidence that such compounds exist... the examples of the '881 patent do not produce the postulated compounds... there is ... no evidence that such compounds even exist." The same circumstance appears to be true here: there is no evidence that solvates of these compounds actually exist; if they did, they would have formed. Hence, applicants must show that solvates can be made, or limit the claims accordingly.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

- 4. Claims 1-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:
 - a) Claims 1-25 are vague and indefinite in that it is not known what is meant by the variable z. It is believed that the applicants intended the letter upper case

Application/Control Number: 10/724,179 Page 7

Art Unit: 1624

b) Claims 1-25 are vague and indefinite in that it is not known what is meant by the definition of Z where there is no variable "Z" in formula [I].

c) Claims 1-25 are vague and indefinite in that it is not known what is meant by the definition of R where there is no variable "R" in formula [I].

Election/Restrictions

5. Claims 26-37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on February 27, 2006.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brenda L. Coleman whose telephone number is 571-272-0665. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Application/Control Number: 10/724,179

Art Unit: 1624

Page 8

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brenda L. Coleman

Primary Examiner Art Unit 1624

November 17, 2006